Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02938793
Title Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Greenville Health System
Indications
Therapies
Age Groups:
Covered Countries USA


No variant requirements are available.